Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis

Journal of Medical Economics
Brian C SauerGrant W Cannon

Abstract

To determine annual biologic drug and administration costs to the US Veterans Health Administration (VHA) per treated patient with rheumatoid arthritis (RA), psoriasis (PsO), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) who received abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab, or ustekinumab. Adults with at least one biologic claim between January 1, 2008 and December 31, 2011 were included. Evidence of enrollment in the VHA was required from 365 days before (pre-index) to 360 days after (post-index) the date of the first biologic claim (index date). Included patients had pre-index diagnoses of RA, PsO, PsA, and/or AS. Drug costs were from Federal Supply Schedule or 'Big Four' in November 2014. Administration costs were VHA fixed costs for infused ($169) and subcutaneous ($25) biologics. Of the 20,465 patients in the analysis, 10,711 received etanercept, 7838 received adalimumab, and 1196 received infliximab as the index biologic. In these patients, across all uses studied, the VHA incurred greater annual cost per treated patient for infliximab ($18,066) compared with adalimumab ($16,523) and etanercept ($16,526). In the first year post-index, ∼80% of patient...Continue Reading

References

Jan 1, 2008·Arthritis and Rheumatism·Charles G HelmickUNKNOWN National Arthritis Data Workgroup
Mar 2, 2010·Arthritis and Rheumatism·Elena MyasoedovaSherine E Gabriel
Dec 31, 2011·The Journal of the American Academy of Orthopaedic Surgeons·Michael Sean DayMark Figgie
Apr 6, 2013·BMC Medicine·Ziv RosmanGisele Zandman-Goddard
Sep 4, 2013·Immunotherapy·Florian M P MeierUlf Müller-Ladner
Dec 11, 2013·Rheumatology·Linda E DeanGary J Macfarlane
Feb 19, 2014·Journal of Autoimmunity·Siba P Raychaudhuri, Atul Deodhar
Apr 22, 2014·American Journal of Preventive Medicine·Charles G HelmickChristopher L Bartlett
Jul 10, 2014·Health Affairs·Stephan D FihnGail L Graham
Sep 24, 2014·ClinicoEconomics and Outcomes Research : CEOR·Machaon BonafedeDavid J Harrison
Nov 18, 2014·Pharmacoepidemiology and Drug Safety·Scott D NelsonBrian Sauer

❮ Previous
Next ❯

Citations

May 23, 2019·Current Opinion in Rheumatology·Jeffrey R Curtis
May 14, 2019·Current Medical Research and Opinion·Sara HigaAasthaa Bansal
Jan 8, 2021·Rheumatology Advances in Practice·Kirk GealeElke Theander

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.